Navigation Links
Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals' Obeticholic Acid (INT-747) in NASH
Date:3/29/2011

NEW YORK, March 29, 2011 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis (NASH), which will evaluate Intercept's first-in-class farnesoid X receptor (FXR) agonist obeticholic acid (OCA) as a novel therapy for NASH. The FXR Ligand NASH Treatment (FLINT) trial is a double blind, placebo controlled, multi-center clinical study that will evaluate the effects of OCA compared with placebo in adult NASH patients.

NASH is a more serious form of nonalcoholic fatty liver disease (NAFLD) and occurs in patients who drink little or no alcohol. The disease is believed to be caused by abnormal metabolism of fats and, although it is often associated with obesity and insulin resistance, it also occurs in lean individuals. NASH is associated with fibrosis (scarring) in the liver that may lead to cirrhosis, liver cancer and death, and the disease also carries an additional mortality risk due to heart disease. NASH is now the most common liver disease in the developed world, affecting at least 3-5% of the U.S. population and up to 50% of patients with morbid obesity.  There is currently no approved treatment for the disease.

FLINT will enroll 280 patients at the eight U.S. centers comprising the NIDDK-sponsored NASH Clinical Research Network.  The primary endpoint in the 72 week study will be determined by liver biopsy and is defined as an improvement in the NAFLD activity score with no worsening of liver fibrosis.  NIDDK is providing the majority of funding for the study and is partnering with Intercept under a cooperative research and development agreement (CRADA).

"It is a privilege to be collaborating with this group of leading NASH investigators and the NIDDK," commented David Shapiro, MD, Chief Medical O
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
4. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
5. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
8. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
9. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014  Advanced Medical Isotope ... company engaged primarily in the development of brachytherapy ... applications, today announced that a Life Sciences Discovery ... awarded for which AMIC is the commercialization partner.  ... (WSU) for the proposal titled "Optimized Injectable Radiogels ...
(Date:12/19/2014)... 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch America" ... to provide this review of the Company,s recent achievements ... "Over this past year, we achieved many of ... proud to say that Monarch America is in a ... ever been," stated Eric Hagen , CEO of ...
(Date:12/19/2014)... 18, 2014  Sage Analytics ( www.sageanalytics.com ), ... for the testing of marijuana potency and moisture ... Luminary™ Profiler, the industry,s first product suite capable ... cost-effective, portable unit. Designed from the ... the cannabis industry, the Luminary™ Profiler utilizes specially ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... NEWARK, N.J., April 6, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... that the New York Stock Exchange (the "NYSE") has notified ... rules due to the Company,s failure to timely file its ... Commission. Under NYSE rules, when a Company ...
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ... of modafinil tablets, a generic version of Teva,s Provigil® ... the Provigil® product.  Par acquired the U.S. marketing rights ... of Cephalon in 2011.  According to IMS Health data, ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2Par Pharmaceutical Begins Shipment of Generic Provigil® 2
(Date:12/21/2014)... December 21, 2014 As testosterone ... heart attacks, stroke and blood clots from using testosterone ... a new study shows that the male hormone testosterone ... In a study published in the Proceedings of the ... Amos-Landgraf examined a group of male rats with naturally ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation hosted ... Whittier offices. The Hope for the Holidays Toy Drive is ... their families during the holiday season. This year, the toy ... between both offices. This event continues to be successful year ... team, store managers and assistant managers came out and not ...
(Date:12/20/2014)... BambooIndustry.com is a professional company offering many kinds ... shown its new engineered bamboo flooring collection, and announced ... , BambooIndustry.com’s customers come from many countries in the ... the CEO of the company, the global bamboo flooring ... few years, and the demand for eco-friendly bamboo flooring ...
(Date:12/20/2014)... (PRWEB) December 21, 2014 MissyDress, a ... for all prom lovers. The business has drastically cut ... prom dresses to everyone until Jan. 30, 2015. Many ... dresses, sweetheart dresses, V-neck dresses, lace dresses, and more. ... are not there every day. Whether A-line princess prom ...
(Date:12/20/2014)... December 20, 2014 An improving macroeconomic ... have benefited the Massage Services industry over ... of industry products, the anticipated 1.0% annualized increase in ... provided consumers with the means to afford additional massages. ... a massage in a given year has declined from ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... did language evolve? While the answer might seem obvious ... and other students of communication have debated this question for ... that language is, in fact, poorly designed for communication. Such ... system that probably evolved for other reasons perhaps for ...
... earlier generations, and even the best perform less well. Researchers ... major long-term health impact. The conclusions about the physical ... schoolchildren,s performance in the 3 000-metre race from 1969 to ... Dyrstad at the University of Stavanger (UiS) have drawn on ...
... House effort to ensure that America,s military heroes receive care ... David Geffen School of Medicine at UCLA have pledged to ... care to help train physicians to meet the special needs ... Joining Forces, an initiative launched by first lady Michelle ...
... of two studies suggest that a new, investigational colorectal ... Mayo Clinic and Exact Sciences Inc. of Madison, Wis., ... noninvasive tests at detecting precancerous tumors (adenomas) and early-stage ... tens of thousands of Americans. Early detection is a ...
... made illegal in the UK in 2010, the street price of ... turn may have reduced use of the drug. New research ... mephedrone after it became illegal would switch to a new legal ... or on the Internet. They would be less deterred by ...
... electronic health records (EHRs) are rapidly becoming part of ... providers of care. In the first large study of ... of Nursing determined that nurses working with EHRs consistently ... outcomes for patients than nurses working in hospitals without ...
Cached Medicine News:Health News:MIT: The advantage of ambiguity in language 2Health News:MIT: The advantage of ambiguity in language 3Health News:Sitting it out 2Health News:Sitting it out 3Health News:UCLA joins forces with White House to meet unique needs of veterans, families 2Health News:UCLA joins forces with White House to meet unique needs of veterans, families 3Health News:UCLA joins forces with White House to meet unique needs of veterans, families 4Health News:New test offers greater accuracy in early detection of colorectal cancer 2Health News:New test offers greater accuracy in early detection of colorectal cancer 3Health News:Despite the risks, mephedrone users in the UK are ready to try the next legal high 2Health News:Better together - The RN and the EHR 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: